About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that ... for people with cancer, cardiovascular and other ...

In the Japan business unit, sales of Lixiana, a direct oral anticoagulant; Tarlige analgesic; and ENHERTU, an anti-cancer agent increased as did the sales of Daiichi Sankyo Healthcare, while again ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer.

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone therapies.

Disclaimer: This article has been developed and funded by Daiichi Sankyo ... in breast and lung cancer, two of the most common cancers and biggest killers in our society. Precision medicines ...

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of ...

The society also recognized Tampa General ... Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail A new survey sponsored by Daiichi Sankyo ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Authors retain all rights in any data supplements associated with their articles The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of ..

an American Cancer Society Institutional Research Grant, the Life Sciences Research Foundation, and K12CA087723. Schneider has received honoraria from the Academy of Continued Healthcare Learning ...